Retatrutide is a triple agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R); it has demonstrated superior clinical efficacy compared to semaglutide in the treatment of obesity, obesity-related Type 2 diabetes, cardiovascular diseases, and various endocrine and metabolic disorders.
Since our founding, we have consistently adhered to the business philosophy of "Quality First, Customer Foremost, and Reputation-Based." We sincerely hope to collaborate with businesses worldwide to achieve mutual success.
Copyright © 2025 Tianjin Kainuoan Technology Co., Ltd. All Rights Reserved.